Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • WD-40 Company: Initiation of Research Coverage

    William Blair initiated research coverage of WD-40 Company (WDFC $206.18), a leading innovator, marketer, and seller of products that solve problems for consumers in homes and users in workshops and factories around the world.

    Read more

  • The Quarterly Rx: Q1 2026 U.S. Biopharma Recap

    The U.S. biopharma sector demonstrated resilience in the first quarter of 2026, building on its recovery despite geopolitical and macroeconomic uncertainty.

    Read more

  • Latin American Airlines’ Fuel Shock Response

    Latin American airlines are tactically hedging fuel and leveraging stronger market dynamics to better absorb oil-price volatility.

    Watch the video
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures